NCT00746447 - Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC) | Biotech Hunter

Enrollment

648

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

April 30, 2007

Study Completion Date

March 31, 2008

Conditions

Colitis, UlcerativeRecurrence

Interventions

DRUG

mesalamine granules

3.0g mesalamine in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;

DRUG

mesalamine granules

1.5g mesalamine and 1.5g placebo in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;

DRUG

mesalamine granules

0.5g mesalamine and 2.5g placebo in the morning, 0.5g mesalamine at lunch, 0.5g mesalamine in the evening

Trial Locations (1)

Evangelisches Krankenhaus Kalk, Medical Dept., Cologne